PMID- 31829455
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20211204
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 34
IP  - 1
DP  - 2020 Jan
TI  - Recent advances in the role of mammalian target of rapamycin inhibitors on 
      cardiac allograft vasculopathy.
PG  - e13769
LID - 10.1111/ctr.13769 [doi]
AB  - Cardiac allograft vasculopathy (CAV) is a progressive fibroproliferative disease, 
      which contributes to significant morbidity and mortality during long-term 
      follow-up after heart transplantation. Mammalian target of rapamycin (mTOR) 
      inhibitors have favorable effects on endothelial function and reduce intimal 
      proliferation, and their early use after transplantation has been associated with 
      a reduction in the risk of development and progression of CAV. However, there are 
      conflicting reports on the efficacy of these agents in treating established CAV. 
      Most of the data until recently have been based on short-term follow-up, and CAV 
      was assessed by changes in intravascular ultrasound. In this study, we review the 
      mechanism of action of mTOR inhibitors and their protective role in CAV and 
      summarize some of the recent literature, which include long-term follow-up using 
      this class of medications.
CI  - (c) 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Bellumkonda, Lavanya
AU  - Bellumkonda L
AUID- ORCID: 0000-0002-9317-9067
AD  - Division of Cardiology, Department of Medicine, Yale School of Medicine, New 
      Haven, CT, USA.
FAU - Patel, Jignesh
AU  - Patel J
AD  - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191231
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Allografts
MH  - Graft Rejection/drug therapy/etiology/prevention & control
MH  - *Heart Transplantation/adverse effects
MH  - Humans
MH  - *Sirolimus
MH  - TOR Serine-Threonine Kinases
OTO - NOTNLM
OT  - heart (allograft) function/dysfunction
OT  - immunosuppression
OT  - mechanistic target of rapamycin
OT  - rejection: vascular
OT  - vasculopathy
EDAT- 2019/12/13 06:00
MHDA- 2021/06/24 06:00
CRDT- 2019/12/13 06:00
PHST- 2019/08/16 00:00 [received]
PHST- 2019/12/02 00:00 [revised]
PHST- 2019/12/05 00:00 [accepted]
PHST- 2019/12/13 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2019/12/13 06:00 [entrez]
AID - 10.1111/ctr.13769 [doi]
PST - ppublish
SO  - Clin Transplant. 2020 Jan;34(1):e13769. doi: 10.1111/ctr.13769. Epub 2019 Dec 31.